Price $2.87 |
Market Cap
213.6M
|
Sector Health Care |
Div. Growth
-
|
|
P/E
-
|
P/B
-
|
P/S
8.24
|
Dividend %
-
|
|
P/CF
1.6
|
P/FCF
-
|
Op. Cash Flow
-43.5K
|
FCF
-0.7
|
|
Op. Margin
-548.10%
|
Net Margin
-982.20%
|
ROE
202.90%
|
ROI
385.80%
|
|
ROA
-327.80%
|
EPS Growth
36.50%
|
Current Ratio
1.6
|
Debt/Equity
-
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Enzon Pharmaceuticals Inc (ENZN) | $0.38 | - | - | 12.8M | Strong Buy |
| Pernix Therapeutics Holdings I (PTX) | $3.43 | - | - | 40.4M | Strong Buy |
| Perrigo Company PLC (PRGO) | $76.21 | - | 0.80% | 10.89B | Strong Buy |
| Valeant Pharmaceuticals Intl I (VRX) | $17.50 | - | - | 5.89B | Strong Buy |
| Navidea Biopharmaceuticals Inc (NAVB) | $0.48 | - | - | 83.4M | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
